Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
FDA-approved: Relief of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.,Off-label: Treatment of apnea of prematurity (limited use).
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Dyphylline is primarily metabolized by the liver via oxidation, with a smaller portion undergoing N-demethylation and oxidation. It is not metabolized to theophylline. Approximately 80% of the dose is excreted unchanged in the urine, indicating minimal hepatic metabolism.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40% bound to plasma proteins, primarily albumin.
55–65% bound to plasma proteins, primarily albumin.
0.3-0.7 L/kg, approximating total body water; higher in neonates and patients with decreased protein binding (e.g., hepatic disease).
0.4–0.6 L/kg, indicating distribution into total body water.
Oral immediate-release: 100% (well absorbed); Extended-release formulations have comparable bioavailability with slower absorption.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
Cr Cl 50-80 m L/min: 75% of dose; Cr Cl 25-50 m L/min: 50% of dose; Cr Cl <25 m L/min: 25% of dose; hemodialysis: administer after dialysis at 50% of dose.
No dose adjustment required for renal impairment.
No specific Child-Pugh based adjustments established; use with caution in severe hepatic impairment due to potential reduced clearance.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not recommended for use in children; safety and efficacy not established. If used: 3-5 mg/kg orally every 6 hours, titrate to serum levels.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at lower end of dosing (200 mg every 6 hours) due to potential age-related decline in renal function; monitor serum levels and adjust based on Cr Cl.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, glaucoma, diabetes mellitus, severe hypoxemia, hypertension, arrhythmias, congestive heart failure, and renal impairment. Monitor serum levels; toxicity can occur at high doses. Concurrent use with other xanthines may increase toxicity. May cause seizures, arrhythmias, and death if serum levels exceed the therapeutic range.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to dyphylline or any component of the formulation; history of seizure disorder (unless adequately controlled); active gastrointestinal hemorrhage; concurrent use of other xanthine derivatives (e.g., theophylline, caffeine).
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase the risk of side effects like nervousness and palpitations. No other significant food interactions.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. Fetal risks are considered low, but caution is advised during all trimesters.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Diprophylline is excreted into human milk. The M/P ratio is unknown. Potential adverse effects in infants include irritability and poor feeding. Weigh benefits against risks. Consider alternative bronchodilators if possible.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific dose adjustments recommended due to pregnancy. Pharmacokinetic changes in pregnancy may decrease drug clearance; monitor clinical response and adjust dose if needed based on efficacy and toxicity.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
DILOR (diprophylline) is a xanthine bronchodilator less potent than theophylline but with fewer GI side effects; monitor for nausea, tremor, tachycardia; use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders; drug interactions include cimetidine, fluoroquinolones, and oral contraceptives which decrease clearance; theophylline levels are not routinely measured but toxicity can occur at high doses.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not double doses.,Report persistent nausea, vomiting, rapid heartbeat, or chest pain.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Inform all healthcare providers you are taking this medication.,Do not stop abruptly without consulting your doctor.,Store at room temperature away from heat and moisture.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR vs AEROLATE SR, answered by our medical review team.
DILOR is a Bronchodilator that works by DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR is: DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR is classified as Category C. DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot . AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.